From soft-tissue to bone: Clinical presentation of fibrodysplasia ossificans progressiva (FOP)
Commissioned by Ipsen and developed for Medthority. This content is intended for healthcare professionals only and has been reviewed by Ipsen for scientific accuracy.
DSFOP-UK-000013 Date of preparation October 2021
FOP recognition in the pediatric and adult population and importance of increasing disease awareness
Can you imagine living with a condition that turns your muscles and soft-tissues progressively and irreversibly into hard bone? This is what patients with fibrodysplasia ossificans progressiva (FOP) experience1,2.
FOP is an ultra-rare genetic disorder affecting 1.4 in a million people that presents at birth and ultimately leads to shortened lifespan1–3. The genetic cause of the disease has been identified, with almost all patients carrying the same gain-of-function ALK2/ACVR1 gene mutation2
The earliest phenotypic evidence of FOP are bilateral malformations of the great toes at birth and the development of soft-tissue swellings known as ‘flare-ups’, which initially occur along the scalp, upper back and neck1,2. This is followed by the transformation of soft- and connective tissues into ribbons, sheets, and plates of bone via a progressive, cumulative, and irreversible process known as heterotopic ossification (HO)1,2. Typically in FOP, HO begins in the dorsal, axial, cranial, and proximal regions of the body prior to development in the ventral, appendicular, and distal regions2.
In FOP, HO can occur spontaneously or precipitated by injury, falls, fatigue, viral infection, surgical procedures, or biopsies1. This clinical presentation, compounded by lack of awareness of disease characteristics, results in the misdiagnosis of FOP in approximately 53% of patients4. Common misdiagnoses such as cancer, juvenile fibromatosis, and myositis ossificans (Figure 1), can often lead to unnecessary medical intervention, which can precipitate further HO and ultimately lead to progressive disability and immobilization of joints over time4.
Together, the current lack of FOP disease awareness and frequent misdiagnosis have the potential to negatively impact the quality of life of patients and their caregivers, highlighting the clear need for increased disease education.
Focusing on the bilateral great toe malformations (the earliest phenotypic evidence) and soft-tissue swellings (to learn more, please read the second article of this series) (Figure 2), will support early diagnosis of FOP and help to avoid unnecessary interventions, thus limiting disability accumulation. Subsequently, genetic testing to identify ALK2/ACVR1 gene mutations can be used to confirm the clinical diagnosis.
To learn more, stay tuned for next month’s article of the series, which will focus on flare-ups.
FOP, fibrodysplasia ossificans progressiva; HO, heterotopic ossification.
- Baujat G, Choquet R, Bouée S, Jeanbat V, Courouve L, Ruel A, et al. Prevalence of fibrodysplasia ossificans progressiva (FOP) in France: an estimate based on a record linkage of two national databases. Orphanet J Rare Dis. 2017;12:123.
- Shore EM. Fibrodysplasia ossificans progressiva (FOP): a human genetic disorder of extra-skeletal bone formation, or - how does one tissue become another? Wiley Interdiscip Rev Dev Biol. 2012;1:153–65.
- IFOPA. Available at: https://www.ifopa.org/fop_on_inside_edition (accessed October 2021).
- Sherman LA, Cheung K, De Cunto C, Kile S, Pignolo RJ, Kaplan FS. The diagnostic journey in fibrodysplasia ossificans progressiva: insights from the FOP registry. Presented at ASBMR 2020, 11–15 September 2020. Virtual Meeting. P-841.
- Kaplan FS, Al Mukaddam M, Baujat G, Brown M, Cali A, Cho T-J, et al. The medical management of fibrodysplasia ossificans progressiva: current treatment considerations. Proc Intl Clin Council FOP. 2019;1:1–111.